Tg(GFAP-CHRM3*)6Kdmc
Transgene Detail
|
|
| Symbol: |
Tg(GFAP-CHRM3*)6Kdmc |
| Name: |
transgene insertion 6, Kevin D McCarthy |
| MGI ID: |
MGI:6148045 |
| Synonyms: |
GFAP-DREADD 3, GFAP-Gq-DREADD, GFAP-hM3Dq |
| Transgene: |
Tg(GFAP-CHRM3*)6Kdmc Location: unknown
|
| Alliance: |
Tg(GFAP-CHRM3*)6Kdmc page
|
|
| Strain of Origin: |
C3H/HeJ x C57BL/6J
|
|
| Transgene Type: |
|
Transgenic (Inserted expressed sequence) |
| Mutation: |
|
Insertion
|
| |
|
Tg(GFAP-CHRM3*)6Kdmc expresses
1 gene
Transgene expresses:
| Organism |
Expressed Gene |
Homolog in Mouse |
Note |
| human |
CHRM3 (1131) |
|
Expresses a mutation hM3Dq |
|
| |
|
Mutation details: This transgene expresses a modified human CHRM3 sequence (DREADD or hM3dq) under the control of a human GFAP promoter.
The hM3Dq ("DREADD") sequence is a Gq-coupled human M3 muscarinic DREADD (designer receptor exclusively activated by designer drug). To create the hM3Dq sequence, the wildtype human muscarinic 3 receptor (CHRM3) sequence was modified via site-directed mutagenesis to harbor two amino acid substitutions (Y149C<3.33>/A239G<5.46>) that abolish receptor affinity for the native ligand, acetylcholine (ACh), but allow receptor binding and subsequent activation by the small drug-like molecule clozapine-N-oxide (CNO).
(J:215844)
|
|
|
| Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
| Carrying this Mutation: |
Mouse Strains: 1 strain available
Cell Lines: 0 lines available
|
|
| Original: |
J:215844 Agulhon C, et al., Modulation of the autonomic nervous system and behaviour by acute glial cell Gq protein-coupled receptor activation in vivo. J Physiol. 2013 Nov 15;591(Pt 22):5599-609 |
| All: |
10 reference(s) |
|